Abstract
ABSTRACTS: Pentoxifylline (PTXF) is a methylxanthine that modifies leukocyte function and inhibits cytokine release. To evaluate its effects on the cardiovascular manifestations of sepsis secondary to group B streptococci, 14 anesthetized, mechanically ventilated piglets were studied over a 240-min period. Animals were randomly assigned to a treatment group that received a PTXF bolus (20 mg/kg) followed by a continuous infusion of 5 mg/kg/h before and during group B streptococci (1 x 108 colony forming units/kg/min) administration and a control group that received saline as a placebo. Comparison of the hemodynamic measurements and arterial blood gases during the first 90 min of PTXF treatment with those of the control group resulted in the following 90 min values: systemic arterial blood pressure was significantly higher in the PTXF group (89 ± 10 versus 56 ± 30 mm Hg; P < 0.005) as was cardiac output (0.18 ± 0.04 versus 0.10 ± 0.07 L/kg/min; p < 0.005). Pulmonary vascular resistance remained lower in the PTXF-treated animals (135 ± 117 versus 248 ± 119 mm Hg/L/min/kg; P < 0.001), and these animals were less acidotic as measured by pH (7.07 ± 0.2 versus 7.31 ± 0.1; p < 0.05) and base deficit (-15 ± 9 versus −5 ± 2 mmol/ L;p < 0.05). Median survival time was significantly longer in the PTXF group (210 versus 90 min; p < 0.002). These data demonstrate that PLXF can ameliorate some of the deleterious hemodynamic manifestations of group B streptococci sepsis and result in improved survival in a young animal model.
Similar content being viewed by others
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Moral, T., Goldberg, R., Suguihara, C. et al. Effects of Pentoxifylline on the Cardiovascular Manifestations of Group B Streptococcal Sepsis in the Piglet. Pediatr Res 31, 596–600 (1992). https://doi.org/10.1203/00006450-199206000-00012
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1203/00006450-199206000-00012